Back to School: How biopharma can reboot drug development. Access exclusive analysis here

BCX-34 small molecule inhibitor of purine nucleoside phosphorylase (PNP): Update

In each cycle, 5-patient cohorts are given 20, 40, 62.5, or 85 mg BCX-34 twice daily for 4 weeks and

Read the full 204 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE